A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIIB SEC filings page.
Biogen Inc. (BIIB) reported $10.3B in revenue over the twelve months to Sep 30, 2026, up 2.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Biogen's cash conversion remains strong and reinvestment is light, but 2025 profitability weakened despite modest revenue recovery.
FY2025 paired$1.29B of net income with$2.20B of operating cash flow, indicating earnings converted well into cash. With capital expenditures at7.0% of operating cash flow, that conversion yielded$2.05B of free cash flow, so reported earnings were not dependent on heavy reinvestment.
Debt-to-equity was 0.3x in FY2025, while liabilities were
Revenue grew
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biogen Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Biogen Inc. scores 74/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Biogen Inc. scores 31/100 on it among other operating companies.
Biogen Inc. carried $0.34 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.34. With no EBITDA figure for fiscal year 2025, Biogen Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 62/100 among other operating companies measured the same way.
Biogen Inc. held $2.68 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.68. Liquidity ranks operating companies on that ratio, and Biogen Inc. scores 74/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Biogen Inc. scores 87/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Biogen Inc. scores 59/100 on it among other operating companies.
Biogen Inc. passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Biogen Inc. generates $1.71 in operating cash flow ($2.2B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Biogen Inc. generated $2.8B in revenue in Q3 2026. This represents an increase of 10.6% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.
Biogen Inc. reported a net loss of $20.6M in Q3 2026. This represents a decrease of 104.4% from the same quarter a year earlier. Against the prior quarter it is down 121.1%.
Biogen Inc. earned -$0.14 per diluted share (EPS) in Q3 2026. This represents a decrease of 104.4% from the same quarter a year earlier. Against the prior quarter it is down 121.2%.
Not reported for Q3 2026.
Cash & Balance Sheet
Biogen Inc. generated $600.4M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 51.0% from the same quarter a year earlier. Against the prior quarter it is up 47.2%.
Biogen Inc. held $1.3B in cash against $7.3B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Biogen Inc.'s gross margin was 73.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
Biogen Inc.'s net profit margin was -0.7% in Q3 2026, showing the share of revenue converted to profit. This is down 19.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Biogen Inc.'s quarterly ROE was -0.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Not reported for Q3 2026.
Capital Allocation
Biogen Inc. invested $574.0M in research and development in Q3 2026. This represents an increase of 31.6% from the same quarter a year earlier. Against the prior quarter it is up 8.4%.
Biogen Inc. invested $40.4M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 12.6% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.
Not reported for Q3 2026.
BIIB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B+10.6% | $2.7B+3.4% | $2.5B+1.9% | $2.3B-7.1% | $2.5B+2.8% | $2.6B+7.3% | $2.4B+6.1% | $2.5B+2.9% |
| Cost of Revenue | $748.4M+11.0% | $776.9M+28.4% | $661.0M+5.0% | $495.5M-15.1% | $674.4M+5.6% | $605.0M+10.8% | $629.3M+16.1% | $583.5M-5.6% |
| Gross Profit | $2.1B+10.5% | $2.0B-4.0% | $1.8B+0.8% | $1.8B-4.7% | $1.9B+1.8% | $2.0B+6.3% | $1.8B+3.1% | $1.9B+5.8% |
| R&D Expenses | $574.0M+31.6% | $529.6M+32.7% | $539.0M+24.2% | $509.4M-0.8% | $436.1M-15.5% | $399.0M-21.1% | $434.1M-2.5% | $513.3M-7.4% |
| SG&A Expenses | $752.0M+26.4% | $709.7M+21.6% | $607.3M+6.1% | $682.5M+0.4% | $594.8M+1.1% | $583.8M+5.4% | $572.5M-1.5% | $680.0M+11.8% |
| Interest Expense | $87.5M+29.8% | $82.3M+13.4% | $67.6M+12.7% | $67.5M+12.5% | $67.4M+12.7% | $72.6M+18.4% | $60.0M-13.3% | $60.0M-16.1% |
| Income Tax | $11.6M-87.2% | $34.9M-68.0% | $58.2M-17.7% | -$7.1M-128.6% | $90.8M+45.3% | $109.2M-5.1% | $70.7M-1.0% | $24.8M-41.9% |
| Net Income | -$20.6M-104.4% | $97.5M-84.6% | $319.5M+32.8% | -$48.9M-118.3% | $466.5M+20.1% | $634.8M+8.8% | $240.5M-38.9% | $266.7M+6.8% |
| EPS (Basic) | -$0.14-104.4% | $0.66-84.8% | $2.17+31.5% | -$0.33-118.0% | $3.18+19.1% | $4.33+8.0% | $1.65-39.1% | $1.83+6.4% |
| EPS (Diluted) | -$0.14-104.4% | $0.66-84.8% | $2.15+31.1% | -$0.35-119.1% | $3.17+19.2% | $4.33+8.3% | $1.64-39.3% | $1.83+7.0% |
| Diluted Shares (Avg) | 148M+0.5% | 149M+1.4% | 148M+1.2% | N/A | 147M+0.7% | 147M+0.5% | 147M+0.5% | N/A |
Not reported in any period shown, so not listed: Operating Income, EBITDA.
BIIB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.1B+9.7% | $32.1B+13.3% | $29.5B+5.2% | $29.4B+5.0% | $29.2B+3.2% | $28.3B+5.7% | $28.0B+5.5% | $28.0B+4.5% |
| Current Assets | $7.6B-15.1% | $7.3B-8.3% | $9.2B+20.5% | $9.0B+20.3% | $8.9B+30.8% | $8.0B+12.1% | $7.6B+12.9% | $7.5B+8.7% |
| Cash & Equivalents | $1.3B-66.2% | $1.3B-53.4% | $3.4B+30.2% | $3.0B+26.7% | $3.9B+127.3% | $2.8B+44.5% | $2.6B+141.8% | $2.4B+126.2% |
| Short-Term Investments | $0-100.0% | $0 | $900.0M | $807.2Mn/m | $97.6M | N/A | N/A | $0n/m |
| Inventory | $2.2B+0.7% | $2.4B+4.8% | $1.9B-14.3% | $2.2B-11.9% | $2.2B-10.5% | $2.3B-9.2% | $2.3B-9.7% | $2.5B-2.6% |
| Accounts Receivable | N/A | N/A | N/A | $1.3B-4.4% | N/A | N/A | N/A | $1.4B-15.6% |
| Long-Term Investments | $0 | $0 | $465.6M | $431.9Mn/m | N/A | N/A | N/A | $0n/m |
| Goodwill | $7.0B+7.7% | $7.0B+7.7% | $6.5B+0.2% | $6.5B+0.2% | $6.5B+0.1% | $6.5B+4.3% | $6.5B+4.0% | $6.5B+4.2% |
| Total Liabilities | $13.1B+19.4% | $13.2B+23.8% | $10.8B-2.0% | $11.2B-1.3% | $11.0B-8.0% | $10.7B-2.0% | $11.1B-2.6% | $11.3B-5.9% |
| Current Liabilities | $3.9B+18.5% | $3.9B+23.0% | $3.0B-43.4% | $3.3B-39.4% | $3.3B-39.4% | $3.2B+2.4% | $5.3B+64.4% | $5.5B+61.0% |
| Non-Current Liabilities | $9.2B+19.8% | $9.3B+24.1% | $7.8B+36.1% | $7.8B+35.0% | $7.7B+18.1% | $7.5B-3.8% | $5.8B-29.2% | $5.8B-32.6% |
| Long-Term Debt | $7.3B+16.0% | $7.3B+16.0% | $6.3B+38.2% | $6.3B+38.3% | $6.3B+38.3% | $6.3B-0.1% | $4.5B-27.7% | $4.5B-33.0% |
| Total Equity | $18.9B+3.9% | $18.8B+6.9% | $18.7B+9.9% | $18.3B+9.2% | $18.2B+11.3% | $17.6B+11.0% | $17.0B+11.6% | $16.7B+13.0% |
| Retained Earnings | $20.9B+1.7% | $21.0B+4.1% | $20.9B+7.0% | $20.6B+6.7% | $20.6B+8.5% | $20.1B+8.2% | $19.5B+8.2% | $19.3B+9.3% |
BIIB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $640.8M-49.6% | $448.9M+179.0% | $645.5M+148.9% | $511.9M-32.7% | $1.3B+36.0% | $160.9M-74.3% | $259.3M-53.1% | $760.9M+5987.2% |
| Depreciation & Amortization | $241.1M+19.2% | $236.1M+21.5% | $204.4M+11.6% | $200.2M+8.8% | $202.2M+10.6% | $194.3M+22.3% | $183.2M+24.2% | $184.0M+31.3% |
| Stock-Based Compensation | N/A | $161.4M | $84.0M+3.7% | N/A | N/A | N/A | $81.0M+11.3% | N/A |
| Capital Expenditures | $40.4M-12.6% | $40.9M+53.8% | $51.2M+38.0% | $43.9M+11.7% | $46.2M+32.0% | $26.6M-20.6% | $37.1M-19.2% | $39.3M-39.7% |
| Free Cash Flow | $600.4M-51.0% | $408.0M+203.8% | $594.3M+167.5% | $468.0M-35.1% | $1.2B+36.2% | $134.3M-77.3% | $222.2M-56.2% | $721.6Mn/m |
| Investing Cash Flow | -$222.1Mn/m | -$3.8Bn/m | -$209.5Mn/m | -$1.2Bn/m | -$35.1Mn/m | -$57.0M-112.2% | -$47.3Mn/m | -$18.6Mn/m |
| Financing Cash Flow | -$393.8Mn/m | $1.3Bn/m | -$43.8Mn/m | -$137.0M-1834.2% | -$130.2Mn/m | -$11.7Mn/m | -$23.0Mn/m | $7.9Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIIB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3%-0.1pp | 71.6%-5.5pp | 73.3%-0.8pp | 78.3%+2.0pp | 73.4%-0.7pp | 77.1%-0.7pp | 74.1%-2.2pp | 76.2%+2.1pp |
| Net Margin | -0.7%-19.1pp | 3.6%-20.4pp | 12.9%+3.0pp | -2.1%-13.0pp | 18.4%+2.6pp | 24.0%+0.3pp | 9.9%-7.3pp | 10.9%+0.4pp |
| Return on Equity | -0.1%-2.7pp | 0.5%-3.1pp | 1.7%+0.3pp | -0.3%-1.9pp | 2.6%+0.2pp | 3.6%-0.1pp | 1.4%-1.2pp | 1.6%-0.1pp |
| Return on Assets | -0.1%-1.7pp | 0.3%-1.9pp | 1.1%+0.2pp | -0.2%-1.1pp | 1.6%+0.2pp | 2.2%+0.1pp | 0.9%-0.6pp | 0.9%0.0pp |
| Current Ratio | 1.95-0.8x | 1.87-0.6x | 3.06+1.6x | 2.68+1.3x | 2.72+1.5x | 2.50+0.2x | 1.44-0.7x | 1.35-0.6x |
| Debt-to-Equity | 0.390.0x | 0.390.0x | 0.34+0.1x | 0.34+0.1x | 0.35+0.1x | 0.360.0x | 0.27-0.1x | 0.27-0.2x |
| Liabilities-to-Equity | 0.69+0.1x | 0.70+0.1x | 0.58-0.1x | 0.61-0.1x | 0.60-0.1x | 0.61-0.1x | 0.65-0.1x | 0.68-0.1x |
| Asset Turnover | 0.090.0x | 0.090.0x | 0.080.0x | 0.080.0x | 0.090.0x | 0.090.0x | 0.090.0x | 0.090.0x |
| FCF Margin | 21.4%-27.0pp | 14.9%+9.8pp | 24.0%+14.8pp | 20.5%-8.9pp | 48.4%+11.9pp | 5.1%-18.9pp | 9.1%-13.0pp | 29.4%+31.6pp |
Not reported in any period shown, so not listed: Operating Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Biogen Inc. BIIB | FY2025 | $9.9B | $1.3B | 13.1% | $37.1B | 65/100 |
| GSK plc GSK | FY2025 | $43.9B | $7.7B | 17.5% | $98.7B | 57/100 |
| Bristol-Myers Squibb Co. BMY | FY2025 | $48.2B | $7.1B | 14.6% | $125.4B | 49/100 |
| Sanofi SNY | FY2025 | $54.8B | $9.2B | 16.7% | $114.1B | 61/100 |
| Pfizer Inc. PFE | FY2025 | $62.6B | $7.8B | 12.4% | $162.3B | 51/100 |
| Novo Nordisk A/S NVO | FY2025 | $48.6B | $16.1B | 33.1% | $179.4B | 71/100 |
Where Biogen Inc. Ranks
Frequently Asked Questions
Biogen Inc. (BIIB) reported $9.9B in total revenue for fiscal year 2025. This represents a 2.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Biogen Inc. (BIIB) revenue grew by 2.2% year-over-year, from $9.7B to $9.9B in fiscal year 2025.
Yes, Biogen Inc. (BIIB) reported a net income of $347.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.3B, with a net profit margin of 13.1%.
As of fiscal year 2025, Biogen Inc. (BIIB) had $3.0B in cash and equivalents against $6.3B in long-term debt.
Biogen Inc. (BIIB) had a gross margin of 75.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Biogen Inc. (BIIB) had a net profit margin of 13.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Biogen Inc. (BIIB) has a return on equity of 7.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Biogen Inc. (BIIB) generated $2.1B in free cash flow during fiscal year 2025. This represents a -24.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Biogen Inc. (BIIB) generated $2.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Biogen Inc. (BIIB) had $29.4B in total assets as of fiscal year 2025, including both current and long-term assets.
Biogen Inc. (BIIB) invested $153.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Biogen Inc. (BIIB) invested $1.8B in research and development during fiscal year 2025.
Biogen Inc. (BIIB) had a current ratio of 2.68 as of fiscal year 2025, which is generally considered healthy.
Biogen Inc. (BIIB) had a debt-to-equity ratio of 0.34 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Biogen Inc. (BIIB) had a liabilities-to-equity ratio of 0.61 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Biogen Inc. (BIIB) had a return on assets of 4.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Biogen Inc. (BIIB) trades at 107x earnings, its market capitalization divided by $347.5M net income, trailing 12 months to September 30, 2026. The market capitalization is $37.1B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Biogen Inc. (BIIB) trades at 3.6x sales, its market capitalization divided by $10.3B revenue, trailing 12 months to September 30, 2026. The market capitalization is $37.1B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Biogen Inc. (BIIB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Biogen Inc. (BIIB) has an earnings quality ratio of 1.71x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Biogen Inc. (BIIB) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.